

# Clinical and Healthcare Improvement through My Health Record usage and Education in General Practice (CHIME-GP): A study protocol for a cluster-randomised controlled trial

**Andrew Bonney**

University of Wollongong Faculty of Science Medicine and Health

**Christine Metusela** (✉ [metusela@uow.edu.au](mailto:metusela@uow.edu.au))

University of Wollongong Faculty of Science Medicine and Health <https://orcid.org/0000-0001-6106-1809>

**Judy Mullan**

University of Wollongong Faculty of Science Medicine and Health

**Stephen Barnett**

Medcast Pty Ltd

**Joel Rhee**

University of Wollongong Faculty of Science Medicine and Health

**Conrad Kobel**

University of Wollongong Faculty of Science Medicine and Health

**Marijka Batterham**

University of Wollongong Faculty of Science Medicine and Health

---

**Study protocol**

**Keywords:** general practice, primary care, education intervention, health service utilisation

**Posted Date:** March 29th, 2021

**DOI:** <https://doi.org/10.21203/rs.3.rs-55427/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

# Abstract

**Background:** There is international interest in whether improved primary care can lead to a more rational use of health resources and whether the use of a national digital health record system by primary health care professionals can help achieve this goal. This trial (CHIME-GP) will investigate whether a multifaceted education intervention in an Australian general practice setting on the use of a national digital health record system leads to reductions in health-service utilisation and costs.

**Methods:** The trial will be undertaken in Australian general practices. The aim of the research is to evaluate the effectiveness of a web-based educational intervention for general practitioners, regarding use of a national digital health record system, My Health Record (MHR), and rational use of medicines, pathology and imaging. Our target is to recruit 120 general practitioners from urban and regional regions across Australia. We will use a mixed methods approach incorporating a three-arm pragmatic cluster randomised parallel trial and a prospective qualitative inquiry. The effect of the intervention in each arm will be assessed, using the other two arms as controls. The evaluation will synthesise the results embedding qualitative pre/post interviews in the quantitative results to investigate implementation of the intervention, clinical behaviour change and mechanisms such as attitudes, that may influence change. The primary outcome will be an economic analysis of the cost per 100 consultations of selected prescriptions, pathology and radiology test ordering in the six months following the intervention compared with six months prior to the intervention. Secondary outcome measures include the rates per 100 consultations of selected prescriptions, pathology and radiology test ordering six months pre and post intervention; and comparison of knowledge assessment tests pre and post intervention.

**Discussion:** The trial will produce robust health economic analyses on the evidence on educational intervention in reducing unnecessary prescribing, pathology and imaging ordering, and in improving the use of MHR. In addition, the study will contribute to the evidence-base concerning the implementation of interventions to improve the quality of care in primary care practice.

**Trial registration:** Australian New Zealand Clinical Trials Registry ACTRN12620000010998. Registered on 09 January 2020.

<http://www.ANZCTR.org.au/ACTRN12620000010998.aspx>

## Administrative Information

### Note

the numbers in curly brackets in this protocol refer to SPIRIT checklist item numbers. The order of the items has been modified to group similar items (see <http://www.equator-network.org/reporting-guidelines/spirit-2013-statement-defining-standard-protocol-items-for-clinical-trials/>).

Title {1}	<b>Clinical and Healthcare Improvement through My Health Record usage and Education in General Practice (CHIME-GP): A study protocol for a cluster-randomised controlled trial</b>
Trial registration {2a and 2b}	Australian New Zealand Clinical Trials Registry ACTRN12620000010998. Registered on 09 January 2020
Protocol version {3}	Protocol Version 8.
Funding {4}	The Trial is funded by the Australian Digital Health Agency (ADHA). The University of Wollongong is contracted by Medcast Pty Ltd to provide the evaluation.
Author details {5a}	In order: Professor Andrew Bonney Dr Christine Metusela Associate Professor Judy Mullan Associate Professor Stephen Barnett Associate Professor Joel Rhee Dr Conrad Kobel Professor Marijka Batterham
Name and contact information for the trial sponsor {5b}	Australian Digital Health Agency 175 Liverpool Street Sydney NSW 2000
Role of sponsor {5c}	Other than requesting a randomised control-type design, the ADHA has no other role in the study design, data collection, management, analysis or interpretation of the data, writing of the report, decision to submit the report for publication or ultimate authority over any of these activities.

## Introduction

### Background and rationale {6a}

The My Health Record (MHR) system, established in 2012, is the national patient-controlled digital health record system administered by the Australian Digital Health Agency (ADHA). MHR is a secure online summary of patients' health information and all Australians have an MHR unless they chose to opt-out before 31 January 2019. An individual can control what goes into their MHR, and who is allowed to access it. They can choose to share their health information with their doctors, hospitals and other healthcare providers or they can also choose to permanently delete their record. One of the key aims of

the MHR system is to support clinicians by helping to improve medication safety and reduce unnecessary test duplication (1). Our randomized controlled trial (RCT) seeks to evaluate the effectiveness of a multifaceted educational package for clinicians, which will focus on the National Prescribing Service (NPS) 'Choosing Wisely' recommendations for ordering pathology and radiology tests, and medication prescribing (2), as well as integrating MHR into clinical practice. The results of our RCT will highlight the benefits of MHR to clinicians and they will also inform future ADHA policy making decisions and resource allocation.

The rational ordering of pathology and radiology, and appropriate prescription of medications, has significant implications for patient safety and efficient utilisation of healthcare resources and budgets. The literature demonstrates that over- and unnecessary-use of prescriptions and test ordering is a major concern to health systems internationally (3, 4). The unnecessary use of prescriptions and tests drives up health system costs, creates system-wide inefficiencies, and places patients at increased risk of harm (5). There is international momentum to reduce unnecessary medicalisation in order to reduce these risks, supported by peak medical bodies in over 22 countries, including the UK, USA, and Australia. Under the umbrella of 'Choosing Wisely', evidence based, discipline, and country specific recommendations for reducing key unnecessary prescriptions and tests have been developed and made publicly available (2). This study will compare medication prescribing and the ordering of pathology and radiology requests among GPs who receive an education intervention targeting one of these areas based on the Australian NPS 'Choosing Wisely' recommendations. It is hypothesised that there will be a reduction in unnecessary medications and tests (pathology and radiology) being ordered among the GPs receiving the relevant education.

## Education Interventions

Educational interventions have potential for significant changes in clinical behaviour, with effect sizes in three recent systematic reviews of educational interventions showing a reduction in prescriptions by 15–20% (6), a reduction in diagnostic imaging by 10–25% (7) and a reduction in pathology ordering by 10–20% (4). The most effective education-based interventions are those adopting a multifaceted approach, in particular practitioner education and feedback combined with systemic change (4). Interventions that include the use of guidelines, audit, reflective practice (usually by way of clinical audit), workshops and academic detailing indicate the most benefit (3, 8–12). In addition, GP alerting systems combined with practitioner education, including online tools and feedback have demonstrated to be beneficial in changing test ordering practices (13–15). Similarly, clinical decision support technologies and drug usage advice have improved rational prescribing (16, 17). To this end, primary care 'groups' have been shown to effectively allow practitioners to compare ordering and prescribing statistics and receive education (18).

According to the evidence therefore, the deployment of a multifaceted intervention in conjunction with the alerting and audit capacity facilitated by MHR has the potential to augment educational impact and change clinician behaviour. An exemplar of the synergies between education interventions and eHealth

are demonstrated in the Extension for Community Healthcare Outcomes (ECHO) project which utilised telehealth, best practice protocols and multidisciplinary case-based learning to deliver sustained improved Hepatitis C healthcare outcomes in an underserved population (19). However, even in the absence of education interventions, the implementation of eHealth records has proven to be beneficial in areas, such as smoking cessation through increased documentation (20). In addition, eHealth data can be used to facilitate primary care audit and research (21) and can enable reflective practice to explore prescribing and test ordering habits (22).

Pragmatic trials are viewed as a means of rigorously assessing the effectiveness of interventions in real-world settings to assist clinical or policy decision making (23). It is important that policy makers and funders have high quality evidence to support decisions, especially where there are significant clinical safety and financial implications. The extensive literature concerning the uptake of innovations in clinical practice demonstrates that the implementation process is complex, highly variable, non-linear and related to features of the innovation itself, such as the context into which the innovation is intended and the uptake of facilitatory supports (24–26).

Appreciation of the complexities of evaluating implementation of change into health care systems has driven research approaches that have the capacity to describe not only the numeric end-result of the translation activities but also the important individual and system antecedents - what worked for whom, in what circumstances and why? (24, 27). Such 'realist' approaches are important for policy makers to maximise the likelihood of achieving intended policy outcomes and enabling policies to be implemented in congruence with the context of the absorptive capacity of end-users and their environments. Thus, we have proposed a multi-method, inter-disciplinary realist-informed evaluation to maximise the utility of the evaluation findings for the ADHA.

## **Rationale for extending Phase I into Phase II**

This pragmatic trial is an extension of a pilot study (Phase I) which reported promising outcomes from MHR educational intervention (ethics approval 2018/047) (28). Phase I indicated that the intervention and use of MHR in clinical practice, based on general practitioner (GP) responses around intention-to-treat, demonstrated knowledge, skill and attitude changes among GP study participants with regards to evidence-based de-prescribing and ordering of pathology and diagnostic imaging tests. Phase I also demonstrated uptake of an "is this needed" step in participants' clinical reasoning and increased attention to reducing unnecessary healthcare expenditure. GPs reported, post intervention, that they were more motivated to use MHR and were checking it more often, as well as feeling more confident about using it. In addition, there were significant behaviour changes regarding deprescribing. In particular, GPs reported that they discussed de-prescribing with patients more often, reduced rates of prescribing fluticasone (inhaled cortico-steroid), and reduced prescribing of metformin and paracetamol/codeine combinations (among a subset of participants). There was also a significant reduction in test ordering for full blood count (FBC) and liver function tests (LFTs) from pre-intervention to post-intervention. The economic impact measured as part of the intervention, indicated the potential for significant cost savings to the health system. Phase I, however was limited by the following factors:

- Small sample size;
- Lack of a control group;
- Inability to access real-world outcomes to measure changes in clinician behaviour (using quantitative data) over time; and
- Resultant restrictions on health economics analysis.

The current Phase II study is designed to overcome the limitations of Phase I.

## Objectives {7}

The objective of the study is to evaluate the effectiveness of a multifaceted educational intervention for Australian GPs. The educational intervention will be conducted by Medcast Pty Ltd and is designed to support best-practice for prescribing, pathology and diagnostic imaging ordering utilising MHR.

The trial will test the primary hypothesis that:

- the education intervention will result in a reduction in the cost per 100 consultations of specified prescriptions, pathology and radiology test ordering in intervention versus control groups in the six months following the intervention compared with six months prior to the intervention.

Secondary hypotheses include that the intervention will result in:

- a reduction in the rate per 100 consultations of specified prescriptions in intervention versus control groups in the six months prior to the intervention compared with six months following the intervention
- a reduction in the rate per 100 consultations of specified pathology test ordering in intervention versus control groups in the six months prior to the intervention compared with six months following the intervention
- a reduction in the rate per 100 consultations of specifies radiology test ordering in intervention versus control groups in the six months prior to the intervention compared with six months following the intervention
- an improvement in knowledge assessment test scores in intervention versus control groups in tests conducted prior to the intervention compared with following the intervention.

The specified prescriptions, pathology and radiology items are listed in Table 1.

Table 1

Target Choosing Wisely drugs and tests to inform development of educational materials

<b>List of Choosing Wisely based items</b>
<b>Rational Prescribing</b>
Proton pump inhibitors (PPIs)
Diuretics
Inhaled corticosteroids (ICS)
Benzodiazepines
Opiates
Nonsteroidal anti-inflammatory drugs (NSAIDS)
<b>Pathology Ordering</b>
Full Blood Count (FBC)
Urea, creatinine and electrolytes
Liver Function Test (LFT)
Thyroid Function Test (TFT)
Vitamin D
Midstream urine (MSU)
<b>Diagnostic Imaging</b>
Low back pain imaging - lumbosacral spine x-ray, lumbosacral spine CT scan and lumbosacral spine MRI scan

We also aim to assess the health economic impact of the intervention and the contexts and mechanisms associated with the resulting outcomes.

## Trial Design {8}

The design is a pragmatic cluster-randomised three arm parallel trial and a prospective qualitative enquiry. The effect of the intervention in each arm will be assessed, using the other two arms as controls. A schematic diagram of the study design is presented in Fig. 1.

The results will be synthesised in a mixed-methods analysis embedding qualitative pre- and post-intervention interviews in the quantitative results.

Following ethics approval (HE2019/367), the trial was registered with the Australian New Zealand Clinical Trials Registry (ACTRN12620000010998).

## **Methods: Participants, Interventions And Outcomes**

### **Study setting {9}**

The study setting is among community-based primary care physicians (general practitioners - GPs) in Australia. Data will be collected from consenting GPs that participate in the online educational program and assessments, the electronic health records generated by the GP participants, and from telephone interviews with selected participants.

### **Eligibility criteria {10}**

#### **Inclusion criteria**

- GP participants will be eligible for inclusion in the study if they hold an Australian Pharmaceutical Benefits Scheme (PBS) prescriber number and Medicare provider number; undertake clinical work at least one day per week in a primary care practice which has compatible electronic health records with PenCS data extraction tools installed and MHR access

#### **Exclusion criteria:**

- Absence from clinical work for more than 8 weeks over the study period

### **Who will take informed consent? {26a}**

Invitations and Participant Information Sheets (PIS) will be sent to eligible GP participants and their practices, via email or other electronic medium, with two follow-up reminders. GPs who volunteer to be included in the study and their practices will be asked to complete and return a Consent Form which to the UOW research team.

### **Additional consent provisions for collection and use of participant data and biological specimens {26b}**

No additional consent provisions are required for the trial.

## **Interventions**

### **Explanation for the choice of comparators {6b}**

Trial participants will be randomised to one of three parallel arms. Each arm will receive different topic content for prescribing, pathology ordering or imaging ordering as a standardised education process intervention. Each arm will act as controls for each other, for example, participants in the pathology arm will act as controls for the imaging and prescribing arms; participants in the imaging arm will act as controls for the pathology and prescribing arms; and participants in the prescribing arm will act as controls for the imaging and pathology arms. In this manner, the change in clinician behaviour

associated with the education intervention for a given topic content arm can be compared against clinicians receiving the equivalent education process exposure but for different topic content in the other two arms.

## Intervention description {11a}

### Medcast Support QI methodology

The standardised education process will be delivered by Medcast Pty Ltd which uses best practice e-learning development, with a focus on social, interactive learning opportunities, known as the *Medcast Support QI methodology*. The educational theory underlying their work is 'communities of practice' (29), and 'virtual communities of practice in General Practice' (30) with tacit knowledge sharing ("know how"), as well as formal, explicit knowledge sharing ("know what"). Learning experiences are mostly case-based (scenario-based) learning and use a variety of modalities including webinars, self-paced learning, blended activities, quizzes and discussions.

### Intervention

Medcast Pty Ltd will develop and implement the education intervention which will focus on three topic streams running in parallel. The topic streams include a rational prescribing education intervention, a rational pathology-ordering education intervention and a rational diagnostic-imaging education intervention. All three topic streams will explore and reinforce the role of MHR in achieving quality improvement (QI) benefits, and in integrating MHR into clinical practice. The 'Choosing Wisely' recommendations (2), an initiative of the National Prescribing Service Australia, will form the basis of the education content, along with other sources of current evidence-based practice (31–36). The Choosing Wisely recommendations, which are evidence-based, are supplied and endorsed by every peak medical and nursing body in Australia. The prescriptions and tests included in the study are specified a-priori for the education sessions and then assessment. These same tests and prescriptions are assessed across all three arms of the trial 6 months pre- and post-intervention. The intervention pathology tests, imaging tests and prescription medication were chosen based on their frequency in general practice, cost to the PBS and potential for adverse outcomes in patients (7, 9, 10, 37).

Each GP participant will be required to complete pre- and post-intervention assessments for all of the prescribing, pathology and imaging educational domains, as although participants are randomised into one arm of the trial, the other two arms act as controls. This will allow assessment of the knowledge and skills acquisition of the GP participants, attributable to the arm of the intervention they have been randomised into, in comparison with the other arms. See Fig. 2 for a comparison of the educational activities in each arm.

Due to COVID-19 (38) and the disruptions this has made to recruitment we are holding two waves of the education intervention, three months apart, with up to 60 participants in each wave. This will enable us to recruit for a longer period of time and give us the opportunity to meet our recruitment target. It is envisaged that each wave of the educational intervention will be delivered over a period of three months

and that the total estimated time commitment for participants is approximately six hours (refer to Table 2 for the Medcast support QI methodology for the three arms of the intervention).

Table 2  
Steps in the educational intervention

<b>Description / Activities</b>
<p><b>Study information and quiz/case scenarios (30 min)</b></p> <p>Study information pack sent to participants.</p> <p>Participants to complete pre-intervention quiz with case scenarios to test intention-to-treat and current use of MHR.</p>
<p><b>Initial engagement webinar (45–60 min)</b></p> <ul style="list-style-type: none"> <li>● Evening webinar meeting facilitated by expert GPs.</li> <li>● Study information to be presented to participants including key timelines.</li> <li>● Opportunity for Q + A about the study process.</li> <li>● Short didactic presentation introducing the topic relevant to their arm of the trial (safe use of medicines, pathology or radiology)</li> <li>● Introduction to MHR, benefits and application.</li> <li>● Arm-relevant case studies where the theory is applied in practice, plus case study examples.</li> </ul>
<p><b>Online learning module (60 min)</b></p> <ul style="list-style-type: none"> <li>● To include data of national, current trends in inappropriate prescribing and testing ordering, as relevant to each arm of the study.</li> <li>● Information about MHR, the future of MHR and current uptake.</li> <li>● Tips and tricks for engagement, barriers, algorithms that can be used.</li> <li>● Information about where MHR can fit into practice - checking the record, look for duplicates, identifying medications prescribed or test results from elsewhere.</li> <li>● A case study scenario demonstrating using MHR.</li> <li>● Relevant case studies will be incorporated to apply the information delivered in the module.</li> </ul>
<p><b>Clinical Audit - Quality Improvement (30–60 min)</b></p> <ul style="list-style-type: none"> <li>● Study participants will be required to complete a clinical audit (quality improvement) activity related to the study arm that they are in.</li> <li>● The clinical audit activity will involve the collection and analysis of patient data with the intention to implement changes to clinical practice to improve patient outcomes.</li> <li>● No identifying patient information will be collected or reported as part of the audit. The information will only be used by the GP for quality improvement activities.</li> <li>● The information collected as part of the audit will be each participant's reflection on the changes to clinical practice as a result of the study and audit activity.</li> </ul>

Description / Activities
<p><b>Case preparation template for webinars (30 min each)</b></p> <ul style="list-style-type: none"> <li>● To prepare for the second and third case-based webinars study participants will be required to complete a case preparation template related to the study arm that they are in.</li> </ul>
<p><b>Case-based learning webinars / podcast (45–60 min each)</b></p> <ul style="list-style-type: none"> <li>● Webinars (two for each arm) will be held with the participants conducting the patient audits.</li> <li>● The webinars will be facilitated by expert GPs and will provide participants with a virtual network to learn from via case-based learning.</li> <li>● Short case presentations will be delivered during the study period and the participants will discuss the management.</li> <li>● Participants will be encouraged to bring a case presentation from their clinical practice for discussion with the group.</li> <li>● The webinars will be recorded and made available online or as a podcast.</li> <li>● Webinar will be run during lunch time and evening to maximise the options for participation.</li> </ul>
<p><b>Post-intervention quiz/case scenarios (30 min)</b></p> <ul style="list-style-type: none"> <li>● Post intervention case scenarios to assess intention-to-treat and use of MHR.</li> </ul>

## Criteria for discontinuing or modifying allocated interventions {11b}

There are no specific criteria for discontinuation or modification of the intervention.

## Strategies to improve adherence to interventions {11c}

Once enrolled in the education program, participants will receive the standard prompts and reminders regarding the education intervention activities.

## Relevant concomitant care permitted or prohibited during the trial {11d}

There are no restrictions placed upon participants for any other professional activity during the trial.

## Provisions for post-trial care {30}

As an educational activity, there are no provisions made for post-trial care, nor any participant harms expected.

## Outcomes {12}

## Outcome Measures

Primary outcome measure:

- Difference in change in cost per 100 consultations of specified prescriptions, pathology and radiology test ordering in intervention versus control groups for the six months following the intervention compared with six months prior to the intervention.

Secondary outcome measures include:

- Difference in change in rate per 100 consultations of specified prescriptions in intervention versus control groups for the six months following the intervention compared with six months prior to the intervention.
- Difference in change in rate per 100 consultations of specified pathology test ordering in intervention versus control groups for the six months following the intervention compared with six months prior to the intervention.
- Difference in change in rate per 100 consultations of specified radiology test in intervention versus control groups for the six months following the intervention compared with six months prior to the intervention.
- Difference in change in knowledge assessment test results in intervention versus control groups, for tests conducted prior to the intervention compared with following the intervention

To assess GPs' use of MHR in clinical decision-making and integration of MHR into clinical systems, the trial will include semi-structured interviews with approximately 30 participants before and after the intervention (approximately 10 in each arm), the final number depending on the sample at which data saturation has been reached.

## **Economic Impact**

Economic evaluation of the educational intervention will consider the joint cost and effects of strategies aimed at reducing potentially inappropriate prescribing, pathology and imaging, as well as report on intervention costs per session and individuals trained. Quantitative practice change evidence from MHR and GP data audit pre-post intervention will be triangulated with GP self-reported assessment of the impact of training by Medcast. Within the study, cost effectiveness analysis will focus on observed intervention cost and cost offsets and, where appropriate, net incremental cost per reduction in reduced use of potentially inappropriate medicines, pathology and imaging.

## **Participant timeline {13}**

The time schedule of enrolment in the trial, data collection and intervention activities is shown in Table 3 below.

Table 3  
CHIME-GP Trial Timeline

<b>TASK NAME</b>	<b>START</b>	<b>FINISH</b>
<b>Participant Recruitment</b>	<b>January 10 2020</b>	<b>August 31 2020</b>
o Invitations to participate will be communicated in recruitment waves via Medcast, PenCS, ADHA and UOW. Invitations will contain the study participant information sheet and consent forms for participants and practices as well as contact details of the research team.		
o Participants and practices expressing interest will send consent forms to the project officer at the University of Wollongong to be enrolled in the trial.		
<b>Participant Randomisation</b>	<b>January 10 2020</b>	<b>August 31 2020</b>
o Randomisation of participants will occur after consent has been gained by participants and their practices. Each enrolled participant will be randomised into one of the three arms of the trial.		
<b>Data collection pre intervention</b>	<b>January 10 2020</b>	<b>September 10 2020</b>
o A sample of consenting participants will be contacted directly by the research team to arrange qualitative interviews following randomisation.		
o GPs n = 30, 10 in each arm, approximately 30 minutes per interview		
o Pre-trial participant quizzes and case scenario activities will be collected by Medcast June-September 2020		
<b>Intervention period</b>	<b>June 2020</b>	<b>November 2020</b>
o Wave 1 Webinars and Online education modules June - August 2020o		
o Wave 2 Webinars and Online education modules September - November 2020		
<b>Data collection post intervention</b>	<b>September 1 2020</b>	<b>May 31 2021</b>
o The sample of consenting participants will be contacted directly by the research team to arrange follow-up qualitative interviews.		
o GPs n = 30, 10 in each arm, approximately 30 minutes per interview		
o Post-trial participant quizzes and case scenario activities will be collected by Medcast		
<b>Data Extraction</b>	<b>June 1 2021</b>	<b>June 1 2021</b>

TASK NAME	START	FINISH
<ul style="list-style-type: none"> <li>o Electronic Health Record data extraction for period November 2019 - May 2021</li> <li>o GPs n = 40 in each arm, automated de-identified data extraction for six months prior to six months post intervention</li> </ul>		

## Sample size {14}

### Sample size for quantitative data

The study is conservatively powered for testing significance in sub-group analyses (e.g. change in prescribing rates or change in pathology test ordering) with a 1:1 intervention: control allocation. As this is a three-arm trial, the final number of control cases in sub-group analyses will be twice those assumed in these calculations. A medium intervention effect ( $f^2 = 0.15$ ) is detectable at 80% power and  $\alpha = 0.05$  with 55 participants, in a two-arm trial (27.5 in each arm), analysed using a linear mixed model. The generally accepted practice level intra-cluster correlation coefficient (ICC) of GP behavior is 0.05 and an average of three participating GPs per practice will be assumed. This results in a conservatively estimated design effect of 1.1. Thus the target recruitment is a minimum of 31 participants in each of the three arms of the trial ( $n = 93$ ). To allow for 25% attrition, the study will aim to recruit 40 participants in each of the three arms ( $n = 120$ ).

### Sample selection for qualitative data

On the consent form, GP participants will be asked to indicate whether they agree to be contacted for pre and post-intervention interviews. A member of the research team invites participants, by their preferred contact method, to take part in 30 minutes pre and post interviews. The research team will use a purposive sampling approach (maximum diversity sampling) to derive the qualitative study sample, which will take into consideration participant age, sex, clinic size and location.

## Recruitment {15}

Medcast Pty Ltd, PenCS (a health analytics company providing data extraction services for the project), ADHA and the University of Wollongong (UOW) will send invitations to GPs in their pre-existing networks, and other known GP groups, inviting GPs from practices that already have PenCS software installed on their practice computing systems to participate (see also eligibility criteria Sect. 10). The organisations sending out invitations will not have access to any of the email databases except their own.

The invitations will be sent to GPs and their practices, via email or other electronic medium, with two follow-up reminders. If insufficient responses are received after sending two reminders, further invitations to new samples of GPs and practices will be sent in the above fashion (refer also to section 26A). Due to the 2020 global pandemic, COVID-19 (38), and its impact on recruitment into the study, we have extended the recruitment period to eight months instead of the initial plan of four months, to enable the study to

meet the recruitment target. In addition, two further reminder emails will be sent to all GP contacts until the recruitment target is met.

The invitations will have Participant Information Sheets and Consent Forms attached. Interested GPs and their practices can respond by faxing or emailing consent forms to the UOW research team. Individual GPs as well as the responsible officer for practices will be required to complete consent forms (see also Sect. 27). Although consent will be obtained at the practice level and the individual GP level, only data relating to the consenting GPs will be extracted from the clinical information system in each practice.

## **Assignment Of Interventions: Allocation**

### **Sequence generation {16a}**

A stratified randomisation approach will be used to ensure a balance of practice sizes ( $\leq 5$  GPs vs  $\geq 6$  GPs) and rurality. Randomisation will be conducted using the RALLOC command in STATA V15 or higher (StataCorp LLC, College Station Tx). While the study will be analysed at the level of individual participants, in order to minimise contamination of control groups, the education intervention will be randomised at a practice level.

### **Concealment mechanism {16b}**

Randomisation will be carried out by the research team's statisticians to one of the 3 groups. The statisticians will remain blinded as to the education intervention assigned to each group for analysis. The study participants will not be blinded as to allocation.

### **Implementation {16c}**

After receipt of consent forms from practices and their associated GPs, a de-identified list will be compiled of practices and GPs including practice size ( $\leq 5$  GPs vs  $\geq 6$  GPs) remoteness area of the practice (major city or other)<sup>(39)</sup> and number of GPs from the practices participating. No other information regarding the identity of the practice will be supplied. The statisticians (Batterham and Kobel) will apply a computerised stratified randomisation algorithm RALLOC (using STATA) to ensure a balanced allocation across each of the three arms of the trial according to practice size and remoteness area and number of participating GPs. GP participants and their practices will be randomised to one of the three topic streams (intervention arms) on a 1:1:1 basis. The statisticians will provide the project officer the randomisation sequence who will allocate the practices into the three trial arms on a first-come-first served basis. As outlined in the data management sections of the protocol, the statisticians will not have access the coding sheets until after final analysis is completed.

## **Assignment Of Interventions: Blinding**

### **Who will be blinded {17a}**

The statisticians will be blinded as to the intervention allocation for analysis. Trial participants, educators and other research team members will not be blinded.

## **Procedure for unblinding if needed {17b}**

As no clinical treatments will be undertaken, the researchers do not believe there is a situation in which breaking the study codes will be required.

## **Data Collection And Management**

### **Plans for assessment and collection of outcomes {18a}**

#### **Quantitative data collection**

PenCS will create an automatic data extraction macro that will extract relevant de-identified clinical data from the Electronic Health Records (EHRs) of the participating GPs at their participating practices. The de-identified clinical data will be encrypted and securely transferred directly from the GP practice server to a secure UOW data repository. Test quiz data will be collected by Medcast Pty Ltd as part of the education intervention. These data will be securely transferred to the UOW data repository.

#### **Qualitative data collection**

It is planned to interview approximately 30 participants prior to and following the intervention, 10 from each of the three education intervention arms. The final number of participants will be determined by whether data saturation has been reached in the interviews. Data saturation will be assessed as occurring when no new information has been collected over two subsequent interviews. The pre- and post-intervention interviews will be conducted as semi-structured individual 30-minute telephone interviews with practice GPs. The interview questions will be used to elicit perceptions and experiences of using MHR prior to the intervention; perceptions and experiences about the intervention; attitudes and behaviour toward rational prescribing and testing; as well as facilitators and barriers to achieving the expected outcomes of the educational intervention. The interviews will be audio recorded, transcribed verbatim and coded to remove identifiers. The data collected are summarized in Table 4.

Table 4  
Data collection schedule

Study phase	Methods	Participants	Purpose
<b>Phase 1:</b> <b>Before education intervention</b>	Qualitative pre- intervention interviews	GPs approx. 30  (n = 10 in each arm), approx. 30 minutes per interview	To ascertain perceptions and attitudes of participants before the education session intervention.  <ul style="list-style-type: none"> <li>• Baseline context including use of MHR and attitudes and behaviours regarding rational prescribing and testing</li> <li>• Key expectations of the educational intervention</li> <li>• Anticipated outcomes of the intervention</li> <li>• Expected facilitators of, and barriers to, achieving the expected outcomes</li> </ul>
	Quantitative pre-intervention audit of rates of specified prescribing, pathology and imaging ordering and MHR access for 6 months prior to the intervention	GPs n = 40 in each arm, automated de-identified data extraction	To describe baseline rates of selected prescribing, pathology and imaging
	Pre-intervention survey with case scenarios to test intention to prescribe / order and use of MHR	GPs n = 40 in each arm, approx. 30 minutes per participant	To describe baseline knowledge and skills
	Quantitative project uptake data	GPs n = 40 in each arm, automated data extraction	To assess GP engagement with the intervention module completions, webinar attendances and site logins will be collected by Medcast.
<b>Phase 2:</b> <b>After completion of all education interventions</b>	Post-intervention knowledge assessment with case scenarios to test intention to prescribe / order and use of MHR	GPs n = 40 in each arm, approx. 30 minutes per participant	To describe changes from baseline between arms in knowledge and skills

Study phase	Methods	Participants	Purpose
	Qualitative post- intervention interviews	GPs approx. 30 (n = 10 in each arm), approx. 30 min per interview	<p>To ascertain perceptions and attitudes of participant after the education session intervention.</p> <ul style="list-style-type: none"> <li>• Post-intervention context including use of MHR and attitudes and behaviours regarding rational prescribing and testing</li> <li>• The degree to which key expectations of the educational intervention were met</li> <li>• The degree to which the anticipated outcomes of the intervention were met</li> <li>• Facilitators of, and barriers to, achieving the expected outcomes</li> <li>• What worked for whom, where and why?</li> </ul>
	Quantitative Post-intervention audit of rates of selected prescribing, pathology and imaging ordering	GPs n = 40 in each arm, automated de-identified data extraction	To describe changes from baseline rates of selected prescribing, pathology and imaging between arms of the trial
	Mixed methods Synthesis	All	Synthesis and analysis to provide in-depth evaluation of the project.

## Plans to promote participant retention and complete follow-up {18b}

Once enrolled in the education program, participants will receive the standard prompts and reminders regarding education activities that would normally occur when enrolled in an equivalent program under non-trial conditions.

## Data management {19}

The UOW research team has created a Data Management Plan which addresses the separation of Medcast from data collection and analysis. Three data repositories will be established in CloudStor, a secure encrypted UOW approved cloud storage resource with secure password-only access and servers

based in Australia. This will facilitate separation of data from master code sheets and provide access to only those members of the research team who require access to the data. As part of this Data Management Plan, the Medcast team will only have access to the following data:

- GP knowledge Quiz data
- Project uptake data

Repository 1 will be shared between Medcast and UOW research team members. Coded knowledge quiz data will be stored in Repository 1 by Medcast. Following the intervention period Medcast access to Repository 1 will be withdrawn. Repository 2 will be used to store the master coding sheet which links the GP participants' identifying information to a six digit study ID (coding the practice and the individual participant). This repository will also be used to store the randomisation allocation list. This repository will be kept separately and accessible only to the UOW Principal Investigator and project officer. Repository 3 will contain the coded, de-identified clinical audit electronic health record data. Via the PenCS software, de-identified electronic health record audit data will transferred from the practices, coded by the participating clinician's study ID, directly into this repository. This repository will also hold the coded, de-identified qualitative interview audio files and transcripts. This repository will be accessible only to the UOW research team members.

CloudStor, the cloud data platform to be used in the project, is administered by AARNet. UOW is a member of AARNet and CloudStor is a UOW approved research data storage option. CloudStor servers are located in Australia and data stored in CloudStor are encrypted and password protected. Ongoing access to the data will be limited to the UOW research team members involved in analysis and publications.

Hard copies of all consent forms will be stored in a locked filing cabinet in the Department of General Practice at UOW, or password-protected folder on CloudStor if in soft copy form. All data will be kept in accordance with UOW research data policies, stored for five years and thereafter permanently deleted.

## **Confidentiality {27}**

In order to maintain confidentiality and privacy, the researchers will establish secure data storage and management procedures:

A digital record of consenting GPs and practices will be available to Medcast and PenCS by the UOW research team by secure internet file transfer. This is needed as the Medcast research team requires access to identifying information of GPs and practices and identifiable participant knowledge quiz data in order to implement the education intervention and administer the professional development requirements; and PenCS requires identifying information of GPs and practices to perform the data extraction.

The UOW research team will allocate a six-digit study identifier to each consenting GP. The identifying information of the GPs and their study ID will be stored on a coding master-sheet kept securely and separately from all other study data.

The unit-level data from each practice is de-identified on-site by the PenCS software and coded according to the consenting GP generating the data. Only data generated by consenting GPs will be extracted.

The de-identified practice data will be transferred securely directly from the practice server to a secure UOW data repository (as is described in further detail below). Therefore, there is no risk that the data is at risk between points, as it is sent directly to UOW and not housed anywhere but the practice server and the UOW secure data repository.

All qualitative interviews will be digitally recorded and coded, then de-identified by the professional transcription service. Once quality checking of the coded audio files has been performed the original audio files will be deleted. Participants can request removal of their identifying data at any time, and any re-identifiable data up until analysis is complete.

### **Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use {33}**

No laboratory or biological specimens will be collected as part of this research.

## **Statistical Methods**

### **Statistical methods for primary and secondary outcomes {20a}**

The use of a randomised recruitment design and stratified randomisation of the intervention will reduce the potential for sampling bias. The statisticians will be blinded as to participant groups for analysis. Each of the data elements will be statistically analysed using linear mixed models test for between-group (intervention versus control) differences in the change in variables over the course of the study period accounting for any clustering. Where appropriate, analyses will control for demographic (age and sex) and practice environment (size, area-level socioeconomic disadvantage and rurality) variables and include MHR access rates as a covariate.

### **Interim analyses {21b}**

As this is an educational intervention, no interim analyses will be performed.

### **Methods for additional analyses (e.g. subgroup analyses) {20b}**

The method for subgroup analyses will be the same as those for the primary analysis.

## **Qualitative analysis**

We will use a framework analysis approach which will allow us to identify relationships and patterns across the qualitative data. Framework analysis has been widely used in health research (40, 41).

Importantly, framework analysis facilitates an ordered and organised way to compare and contrast data both across multiple cases and within individual cases. We will use the seven-step process proposed by Gale et al (42) to undertake the framework analysis. These steps are 1) transcription; 2) familiarisation; 3) coding; 4) developing a working analytical framework; 5) applying the framework; 6) charting the data; and 7) interpreting the data. By taking this approach we will be able to develop clusters of themes that facilitate both explanatory and descriptive conclusions directly relevant to our study objectives. We will utilise NVivo for the researchers responsible for coding and management of the qualitative data sets. A selection of the data will be double-coded to aid reliability. The researchers will employ reflexivity in the analyses to guard against bias arising from their roles and backgrounds.

### **Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c}**

Data will be analysed on an intention-to-treat basis. That is, where available, data will still be included in the analysis where there has been non-adherence to the educational intervention or loss to follow-up. The planned mixed model statistical analysis is robust to missing data.

### **Plans to give access to the full protocol, participant level-data and statistical code {31c}**

The protocol is publicly available through this publication and the ANZCTR website.

## **Oversight And Monitoring**

### **Composition of the coordinating centre and trial steering committee {5d}**

All Chief Investigators are members of the trial steering committee, which meets every 4 weeks. The steering committee's remit includes data management. It is independent from the sponsor (ADHA). An operations group responsible for the day-to-day conduct of the trial reports to the steering committee and meets weekly.

### **Composition of the data monitoring committee, its role and reporting structure {21a}**

Due to the low risk of harms arising from this educational intervention, the trial steering committee will act as the data monitoring committee. It is independent from the sponsor (ADHA).

### **Adverse event reporting and harms {22}**

Any reports of potential harm from participating GPs will be investigated by the steering committee and, if appropriate, reported to the ethics committee.

### **Frequency and plans for auditing trial conduct {23}**

There will not be any independent trial audit.

## **Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) {25}**

The research team will obtain ethics committee approval for all substantive trial amendments, including changes to recruitment, eligibility, the intervention or outcomes. Where relevant, substantive changes will be communicated to the sponsor (ADHA) via Medcast and to trial participants via the UOW research team.

## **Dissemination Plans {31a}**

Outcomes of the trial and recommendations will be communicated to the trial sponsor, ADHA, via a report and through presentations. The research group will also disseminate the trial findings through publications in peer reviewed journals, conference presentations, professional meetings and plain language summaries on institutional websites.

## **Discussion**

This trial consists of a practice-based intervention implemented in the primary care setting. Through quantitative data collection and analyses the trial is designed to test the effects of education intervention to enable quality improvement in general practice. As part of the trial design, pre and post qualitative interviews are intended to contextualise the quantitative findings and provide insights into the perceptions and experiences of GPs with MHR, their attitude and behaviour toward rational use of medicines, pathology and imaging, and their perceptions about the success or otherwise of the intervention.

The research will evaluate the effectiveness of the educational intervention for GPs, regarding use of MHR and rational testing and prescribing, in achieving the following objectives set by the ADHA: improving practitioner knowledge; changing practitioner behaviour; facilitating incorporation of clinical changes and technology usage into routine care; making meaningful improvements in clinical care and, resulting in tangible economic benefits. Due to the challenges faced by conducting research during COVID-19, two waves of education intervention are planned to enable us to meet our recruitment target.

Exploring and influencing GP habits requires a pragmatic approach. System-based strategies such as protocol-based test ordering and use of clinical guidelines, have been shown to promote rational ordering and cost savings (43, 44). Furthermore, patient engagement and health responsibility is enabled by MHR, encouraging shared decision-making and future possibilities of patient interventions (45). Indeed, improvements in multimorbidity outcomes in primary care have resulted from better case planning and care coordination, further acknowledging the intended benefits of eHealth (46).

Educational interventions in general practice have the potential for significant savings to the Medicare Benefits Scheme (MBS) and Pharmaceutical Benefits Scheme (PBS) - medical services that are subsidised by the Australian government, even with moderate effect sizes of the interventions, with recent systematic reviews demonstrating a number of trials resulting in reductions in prescriptions (6), diagnostic imaging (7) and pathology ordering (4).

An appropriately designed, multifaceted education intervention, coupled with MHR, has the potential to improve quality of care and lower the burden of illness for patients whilst reducing costs from test duplication, polypharmacy and low-value test ordering. This pragmatic cluster-randomised three arm parallel trial is adequately powered to quantify reductions in unnecessary prescribing, pathology and imaging ordering, and capable of producing robust health economic analyses.

## **Trial Status**

The trial is ongoing. Recruitment commenced in January 2020 and will conclude on 31 August 2020. The study was still in the recruitment stage at the time of the protocol manuscript submission. Protocol version 8 April 29 2020.

## **Declarations**

### **Acknowledgements**

The ADHA has commissioned a randomised controlled trial adequately powered to quantify reductions in unnecessary prescribing, pathology and imaging ordering and capable of producing robust health economic analyses.

The authors would like to thank Ms. Alyssa Horgan (Research Officer, University of Wollongong), Ms. Libby McCardle (Project Officer, Medcast), Ms. Jessica McKenzie (PenCS), Ms. Edweana Wenkart (PenCS) and Mr. Cheran Gul (PenCS) for their work in making the trial an operational success. We would also like to thank the general practice participants and their practices for their involvement in the trial, particularly in the current environment of COVID-19.

### **Authors' contributions {31b}**

AB is the lead investigator. All authors (AB, CM, JM, SB, JR, CK, MB) have contributed to the study design process. All authors (AB, CM, JM, SB, JR, CK, MB) made substantial contributions to the conception, design, drafting and revising of this manuscript, and gave approval of the final copy.

### **Funding {4}**

This trial protocol has been granted funding by the Australian Digital Health Agency (ADHA), who issued a competitive Request for Proposals for the study topic. The ADHA will not have any further authority over the study design, analyses or publication.

## **Availability of data and materials {29}**

To protect the privacy and confidentiality of individual GPs, primary data will not be made publicly available.

## **Ethics approval and consent to participate {24}**

Ethics approval was granted by the University of Wollongong Human Research Ethics Committee (approval: 2019/367). All participating GPs, along with their practice must provide written informed consent. The practice of each participating GP will have accessible information and procedures to allow patients to opt-out of the use of their de-identified clinical data for research purposes if they choose.

## **Consent for publication {32}**

Not applicable

## **Competing interests {28}**

The industry partner (Medcast Pty Ltd) will design and implement the education intervention, with input from UOW, and requires access to some identifiable data in order to do so. There is a duality of interest arising from the commercial potential of the outcome for Medcast. This duality of interest will be managed in the following manner: Clin A/Prof Stephen Barnett will be included as a named investigator and responsible for ethical conduct at the Medcast site; All outcome data other than quiz/case scenario data will be collected independently of, and inaccessible, to Medcast; UOW will be solely responsible for quantitative and qualitative data analysis and interpretation. Medcast will not be involved in any data analysis; Medcast will contribute to the study design, recruitment, intervention and quiz/case scenario data collection. Medcast will contribute to reports and publications arising from the study in relation to those aspects of the study only.

## **Abbreviations**

ADHA: Australian Digital Health Agency; ANZCTR: Australian New Zealand Clinical Trials Registry; EHRs: Electronic Health Records; FBC: Full Blood Count; GP: General practitioner; ICC: Intra-cluster Correlation Coefficient; LFTs: Liver Function Tests; MBS: Medicare Benefits Schedule; MHR: My Health Record; PBS: Pharmaceutical Benefits Scheme; PIS: Participant Information Sheet; QI: Quality Improvement; RCT: Randomised Controlled Trial; UOW: University of Wollongong.

## **References**

1. Australian Digital Health Agency. Annual Report 2018–2019. Australian Government, ADHA; 2019. [https://www.digitalhealth.gov.au/about-the-agency/publications/reports/annual-report/Annual\\_Report\\_Australian\\_Digital\\_Health\\_Agency\\_2018-2019\\_Online.pdf](https://www.digitalhealth.gov.au/about-the-agency/publications/reports/annual-report/Annual_Report_Australian_Digital_Health_Agency_2018-2019_Online.pdf). Accessed 30 April 2020.

2. NPS MedicineWise. Choosing Wisely Australia 2019  
<http://www.choosingwisely.org.au/recommendations>. Accessed 30 April 2020.
3. Kamarudin G, Penm J, Chaar B, Moles R. Educational interventions to improve prescribing competency: a systematic review. *BMJ OPEN*. 2013;3(8):e003291.
4. Thomas RE, Vaska M, Naugler C, Chowdhury TT. Interventions to Educate Family Physicians to Change Test Ordering: Systematic Review of Randomized Controlled Trials. *Acad Pathol*. 2016;3.
5. Ross J, Santhirapala R, MacEwen C, Coulter A. Helping patients choose wisely. *BMJ*. 2018;361.
6. Gnjjidic D, Le Couteur DG, Kouladjian L, Hilmer SN. Deprescribing Trials: Methods to Reduce Polypharmacy and the Impact on Prescribing and Clinical Outcomes. *Clin Geriatr Med*. 2012;28(2):237–53.
7. Jenkins MChir HJ, Hancock MJ, French SD, Maher CG, Engel RM, Magnussen JS. Effectiveness of interventions designed to reduce the use of imaging for low-back pain: a systematic review. *CMAJ*. 2015;187(6):401–8.
8. Ajjawi R, Thistlethwaite JE, Aslani P, Cooling NB. What are the perceived learning needs of Australian general practice registrars for quality prescribing?. *BMC Med Educ*. 2010;10(1).
9. Morgan S, Coleman J. We live in testing times: Teaching rational test ordering in general practice. *Aust Fam Physician*. 2014;43(5):273–6.
10. Morgan S, Morgan A, Kerr R, Tapley A, Magin P. Test ordering by GP trainees: Effects of an educational intervention on attitudes and intended practice. *Can Fam Physician*. 2016;62(9):733–41.
11. O'Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J, Kristoffersen DT, et al. Educational outreach visits: effects on professional practice and health care outcomes. *Cochrane Database of Systematic Reviews*. 2007;4.
12. van Driel ML, Morgan S, Tapley A, McArthur L, McElduff P, Yardley L, et al. Changing the Antibiotic Prescribing of general practice registrars: the ChAP study protocol for a prospective controlled study of a multimodal educational intervention. *BMC Family Practice*. 2016;17(1):67.
13. Kumar RK, Webber K, Gilbert C, Pryor W. An online tool to help doctors learn about the rational use of diagnostic investigations. *Focus on Health Professional Education: A Multi-disciplinary Journal*. 2014;15(3):94–8.
14. Tzortziou BV, Underwood M, Mohamed N, Westwood O, Morrissey D. Professional interventions for general practitioners on the management of musculoskeletal conditions. *Cochrane Database of Systematic Reviews*. 2016;5.
15. Zwar NA, Gordon JJ, Sanson-Fisher RW. Evaluation of an educational program in rational prescribing for GP trainees. *Aust Fam Physician*. 1995;24(5):833–8.
16. Alldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. *Cochrane Database of Systematic Reviews*. 2016.
17. Gillaizeau F, Chan E, Trinquart L, Colombet I, Walton R, Rège-Walther M, et al. Computerized advice on drug dosage to improve prescribing practice. *Cochrane Database of Systematic Reviews*. 2013;11.


18. Walker J, Mathers N. The impact of a general practice group intervention on prescribing costs and patterns. *Br J Gen Pract.* 2002;52(476):181–6.
19. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, et al. Expanding Access to HCV Treatment - Extension for Community Healthcare Outcomes (ECHO) Project: Disruptive Innovation in Specialty Care. *Hepatology.* 2010;52(3):1124–33.
20. Boyle R, Solberg L, Fiore M. Use of electronic health records to support smoking cessation. *Cochrane Database of Systematic Reviews.* 2014.
21. Barnett S, Henderson J, Hodgkins A, Harrison C, Ghosh A, Dijkmans-Hadley B, et al. A valuable approach to the use of electronic medical data in primary care research: Panning for gold. *Health Inf Manag.* 2016;46(2):51–7.
22. Majeed A, Evans N, Head P. What can PACT tell us about prescribing in general practice? *BMJ.* 1997;315(7121):1515–9.
23. Ford I, Norrie J. Should real-world evidence be incorporated into regulatory approvals? *The New England Journal of Medicine.* 2016;375(5).
24. Greenhalgh T. *How to Implement Evidence-Based Healthcare.* Oxford: John Wiley & Sons Ltd; 2018.
25. Greenhalgh T, Robert G, Bate P, Kyriakidou O, Mcfarlane F, Peacock R. *How to spread good ideas: A systematic review of the literature on diffusion, spread and sustainability of innovations in health service delivery and organisation.* London: NHS Service Delivery Organisation; 2004.
26. Harvey G, Kitson A. *Implementing Evidence-Based Practice in Healthcare: A Facilitation Guide.* London: Routledge; 2015.
27. Marchal B, van Belle S, van Olmen J, Hoérée T, Kegels G. Is realist evaluation keeping its promise? A review of published empirical studies in the field of health systems research. *Evaluation.* 2012;18(2):192–212.
28. Bonney A, Dijkmans-Hadley B, Kobel C, Nunes J, Rhee J. *Evaluation of a multifaceted intervention to change clinical practice using My Health Record (MHR) in primary care – final report to the Australian Digital Health Agency University of Wollongong;* 2018.
29. Wenger E. *Communities of practice: a brief introduction.* National Science Foundation. 2011.
30. Barnett S, Jones SC, Bennet S, Iverson DC, Bonney A. General practice training and virtual communities of practice - a review of the literature. *BMC Family Practice.* 2012;13:87–109.
31. Agency for healthcare research and quality. *The Effectiveness and Risks of Long-term Opioid Treatment of Chronic Pain: Systematic Review Protocol.* 2013. Accessed 30 July 2020.
32. Maher CG, Williams C, Lin C, Latimer J. Managing low back pain in primary care. *Aust Prescr.* 2011;34:128–32.
33. Morgan S, van Driel M, Coleman J, Magin P. Rational test ordering in family medicine. *Can Fam Physician.* 2015;61(6):535–7.
34. Philips PJ. HbA1c and monitoring glycaemia. *Aust Fam Physician.* 2012;41(1):37–40.

35. Scott IA, Anderson K, Freeman CR, Stowasser DA. First do no harm: a real need to deprescribe in older patients. *Med J Aust.* 2014;201(7):390–2.
36. Spelman D. Inappropriate pathology ordering and pathology stewardship. *Med J Aust.* 2015;202(1):13–6.
37. Harrison C, Charles J, Henderson J, Britt H. Opioid prescribing in Australian general practice. *Med J Aust.* 2012;196(6):380–1.
38. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19–11 March 2020: W.H.O; 2020 <https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020>. Accessed 30 April 2020.
39. Australian Bureau of Statistics. Remoteness structure: ABS; 2014 <http://www.abs.gov.au/websitedbs/d3310114.nsf/home/remoteness+structure>. Accessed 30 April 2020.
40. Ritchie J, Lewis J. *Qualitative research practice: a guide for social science students and researchers.* London: Sage Publications; 2003.
41. Smith J, Firth J. Qualitative data analysis: the framework approach. *Nurse Res.* 2011;18(2):52–62.
42. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. *BMC Medical Research Methodology.* 2013;13.
43. Gardiner F, Zhai S. Appropriate pathology ordering? Troponin testing within an Australian Emergency Department. *Ir J Med Sci.* 2017;186(1):213–8.
44. MacPherson RD, Reeve SA, Stewart TV, Cunningham AE, Craven ML, Fox G, et al. Effective strategy to guide pathology test ordering in surgical patients. *ANZ J Surg.* 2005;75:138–43.
45. Ammenwerth E, Lannig S, Hörbst A, Muller G, Schnell-Inderst P. Adult patient access to electronic health records. *Cochrane Database of Systematic Reviews.* 2017;6.
46. Smith SM, Wallace E, O'Dowd T, Fortin M. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. *Cochrane Database of Systematic Reviews.* 2016;3.

## Figures

INTERVENTION EDUCATION      CONTROL EDUCATION

(n= individual participants)



**Figure 1**

Study design

Deprescribing arm	Pathology arm	Imaging arm
<ul style="list-style-type: none"> <li>• Pre-intervention survey - with case scenarios to test intention to deprescribe, reduce pathology and imaging tests and use of MHR</li> <li>• Initial engagement webinar - including study information and education on deprescribing <ul style="list-style-type: none"> <li>• Participants to be given snapshot of current PBS national prescribing habits</li> </ul> </li> <li>• Online education module - to reinforce key messages from the webinar and using case studies to apply knowledge</li> <li>• Audit - Over the study period, participants will be required to identify five patients in the target group and then enter the outcomes of their deprescribing discussion (not-identifiable) into an online audit form</li> <li>• Webinars - During the study period 2 x follow up webinars will be conducted that will feature case studies and are designed as a small group learning session</li> <li>• Post-intervention survey - with case scenarios to test intention to deprescribe, reduce pathology and imaging tests, and use of MHR</li> </ul>	<ul style="list-style-type: none"> <li>• Pre-intervention survey - with case scenarios to test intention to deprescribe, reduce pathology and imaging tests and use of MHR</li> <li>• Initial engagement webinar - including study information and education on rational use of tests <ul style="list-style-type: none"> <li>• Participants to be given a snapshot of current national MBS pathology ordering habits</li> </ul> </li> <li>• Online education module - to reinforce key messages from the webinar and using case studies to apply knowledge</li> <li>• Audit - over the study period, participants to identify five patients in the target group and then enter the outcomes of their pathology rationalisation discussion (not-identifiable) into online audit form</li> <li>• Webinars - during the study period, 2 x follow-up webinars will be conducted, featuring case-based presentations and a small group learning session</li> <li>• Post-intervention survey - with case scenarios to test intention to deprescribe, reduce pathology and imaging tests, and use of MHR</li> </ul>	<ul style="list-style-type: none"> <li>• Pre-intervention survey - with case scenarios to test intention to deprescribe, reduce pathology and imaging tests and use of MHR</li> <li>• Initial engagement webinar including study information and education on rational use of imaging <ul style="list-style-type: none"> <li>• Participants to be given snapshot of current national MBS diagnostic imaging ordering patterns.</li> </ul> </li> <li>• Online education module - to reinforce key messages from the webinar and using case studies to apply knowledge</li> <li>• Audit - over the study period, participants to identify five patients in the target group and then enter the outcomes of their pathology rationalisation discussion (not-identifiable) into online audit form</li> <li>• Webinars - During the study period, 2 x follow-up webinars - featuring case studies in a small group learning format</li> <li>• Post-intervention survey - with case scenarios to test intention to deprescribe, reduce pathology and imaging tests, and use of MHR</li> </ul>

**Figure 2**

Description of Education Intervention activities for each arm